Search the database for deliberate release of GM medicinal products

Displaying 1 - 1 of 1
EU record number Title Company / Sponsor Treated organism Genetic modification
Only notified under the "contained use" procedure. Dossier submitted on . A Phase 3, Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of BMS-986353, CD-19-targeted NEXT-T CAR-T Cells, Versus Standard of Care in Participants with Active Systemic Sclerosis (Breakfree-SSc) Celgene Humans CD19 CAR

© Sciensano - Version 1.0 (20260902.1)